Kymera Therapeutics is approaching a high-stakes clinical catalyst for KT-621 in eczema, with the company planning to announce mid-stage data before the end of the year. The investment market is treating the readout as one of the most impactful immunology and inflammatory-disorders updates of 2026. The asset is positioned as a potential rival to Dupixent, with Jefferies describing the upcoming decision point as highly consequential. Depending on how efficacy and safety read out, the results could reshape expectations for Kymera’s ability to expand into a broader immunology footprint, including chronic spontaneous urticaria and asthma. Analysts cited by STAT+ project eczema-driven sales could reach nearly $4 billion by 2035, including more than $3 billion from eczema. For now, the key near-term event is the timing and quality of the eczema data release that investors expect to guide the company’s next development and partnership decisions.